Diagnosing prodromal Alzheimer's disease: Role of CSF biochemical markers
Authors:
- Lucilla ParnettiLucilla Parnetti
- Alessia LanariALAlessia Lanari
- Giorgio SilvestrelliGSGiorgio Silvestrelli
- Emanuele SaggeseESEmanuele Saggese
- Paolo ReboldiPRPaolo Reboldi
- 1 February 2006
- journal article
- Published by Elsevier in Mechanisms of Ageing and Development
- Vol. 127 (2) , 129-132
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Amnestic MCI or prodromal Alzheimer's disease?The Lancet Neurology, 2004
- Core biological marker candidates of Alzheimer?s disease ? perspectives for diagnosis, prediction of outcome and reflection of biological activityJournal of Neural Transmission, 2004
- CSF markers for incipient Alzheimer's diseaseThe Lancet Neurology, 2003
- The Diagnosis of Alzheimer Disease Before It Is Alzheimer DementiaArchives of Neurology, 2003
- CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjectsNeurology, 2002
- CSF Total tau, Aβ42 and Phosphorylated tau Protein as Biomarkers for Alzheimer's DiseaseMolecular Neurobiology, 2001
- Cerebrospinal fluid tau and Aβ42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairmentNeuroscience Letters, 1999
- Evolution of neuronal changes in the course of Alzheimer’s disease1998
- Staging of alzheimer's disease-related neurofibrillary changesNeurobiology of Aging, 1995
- A4 amyloid protein deposition and the diagnosis of Alzheimer's diseaseNeurology, 1988